{
    "doi": "https://doi.org/10.1182/blood.V118.21.783.783",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2073",
    "start_url_page_num": 2073,
    "is_scraped": "1",
    "article_title": "Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients \u2013 a Follow-up Analysis of the German CML Study IV ",
    "article_date": "November 18, 2011",
    "session_type": "632. Chronic Myeloid Leukemia - Therapy: Prediction of Response",
    "topics": [
        "cytogenetics",
        "disease progression",
        "follow-up",
        "imatinib mesylate",
        "leukemia, myelocytic, chronic",
        "bcr-abl tyrosine kinase",
        "protein-tyrosine kinase inhibitor",
        "accelerated phase",
        "cytarabine",
        "interferon-alpha"
    ],
    "author_names": [
        "Benjamin Hanfstein, MD",
        "Martin C. Mu\u0308ller, MD",
        "Philipp Erben, MD",
        "Michael Lauseker",
        "Susanne Saussele, MD",
        "Ulrike Proetel, MD",
        "Susanne Schnittger, PhD",
        "Claudia Haferlach, MD",
        "Hans-Jochem Kolb, MD",
        "Stefan W. Krause, MD",
        "Christoph Nerl, MD",
        "Dominik Heim, MD",
        "Gabriela M. Baerlocher, MD",
        "Jo\u0308rg E. A. Schubert, MD",
        "Hermann Einsele, MD",
        "Mathias Ha\u0308nel, MD",
        "Jolanta Dengler, MD",
        "Christiane Falge, MD",
        "Lothar Kanz, MD",
        "Andreas Neubauer, MD",
        "Michael Kneba, MD",
        "Frank Stegelmann, MD",
        "Michael Pfreundschuh, MD",
        "Cornelius F. Waller, MD",
        "Markus Pfirrmann, PhD",
        "Jo\u0308rg Hasford, MD",
        "Wolf-Karsten Hofmann, MD",
        "Ru\u0308diger Hehlmann, MD",
        "Andreas Hochhaus, MD",
        "for The SAKK",
        "for The German CML Study Group"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "MLL, Mu\u0308nchner Leuka\u0308mie Labor, Mu\u0308nchen, Germany, "
        ],
        [
            "MLL, Mu\u0308nchner Leuka\u0308mie Labor, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Universita\u0308t Mu\u0308nchen-Gro \u00dfhadern, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik 5, Universita\u0308tsklinikum Erlangen, Erlangen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Krankenhaus Mu\u0308nchen-Schwabing, Mu\u0308nchen, Germany, "
        ],
        [
            "Deptartment of Hematology, Universita\u0308tsspital Basel, Basel, Switzerland, "
        ],
        [
            "Universita\u0308tsklinik fu\u0308r Ha\u0308matologie, Inselspital Bern, Bern, Switzerland, "
        ],
        [
            "Abteilung fu\u0308r Ha\u0308matologie/Onkologie, Evangelisches Krankenhaus Hamm, Hamm, Germany, "
        ],
        [
            "Medizinische Klinik II, Universita\u0308tsklinikum Wu\u0308rzburg, Wu\u0308rzburg, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Klinikum Chemnitz, Chemnitz, Germany, "
        ],
        [
            "Innere Medizin V, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany, "
        ],
        [
            "Medizinische Klinik 5, Klinikum Nu\u0308rnberg Nord, Nu\u0308rnberg, Germany, "
        ],
        [
            "Innere Medizin II, Universita\u0308tsklinikum Tu\u0308bingen, Tu\u0308bingen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Zentrum Innere Medizin, Philipps-Universita\u0308t Marburg, Marburg, Germany, "
        ],
        [
            "II. Medizinische Klinik und Poliklinik, Universita\u0308tsklinikum Schleswig-Holstein, Kiel, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Universita\u0308tsklinikum Ulm, Ulm, Germany, "
        ],
        [
            "Innere Medizin I, Universita\u0308tsklinikum des Saarlandes, Homburg, Germany, "
        ],
        [
            "Innere Medizin 1, Universita\u0308tsklinikum Freiburg, Freiburg, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Mu\u0308nchen, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Medizinische Fakulta\u0308t Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany, "
        ],
        [
            "Hematology/Oncology, Universita\u0308tsklinikum Jena, Jena, Germany"
        ],
        [],
        []
    ],
    "first_author_latitude": "49.4924375",
    "first_author_longitude": "8.486733399999999",
    "abstract_text": "Abstract 783 FN2 Introduction: The advent of second generation tyrosine kinase inhibitors (TKI) in the front line treatment setting of chronic myeloid leukemia (CML) has tightened the evaluation of imatinib response. Early assessment of response markers might identify slow responders harboring a BCR-ABL positive clone with an inferior susceptibility to tyrosine kinase inhibition. This group of patients could benefit from an early dose escalation or a change of treatment to a second generation TKI thus avoiding the risk of disease progression. Therefore we sought to evaluate the impact of molecular and cytogenetic response levels after 3 months of imatinib treatment on the further course of disease. Patients and methods: A total of 1,340 patients (median age 52 years, range 16\u201388, 40% female) were included into the randomized German CML study IV and treated with an imatinib based therapy consisting of imatinib 400 mg/d (n=381), imatinib 800 mg/d (n=399) and combinations of standard dose imatinib with interferon alpha (n=402) and low-dose cytarabine (n=158). Median follow-up was 4.7 years (range 0\u20139). Molecular response after 3 months was assessed in 743 patients, cytogenetic response in 498 patients. The BCR-ABL expression was determined by quantitative RT-PCR and standardized according to the international scale (BCR-ABL IS). Only patients expressing typical BCR-ABL transcripts (b2a2, b3a2, b2a2 and b3a2) were considered. Cytogenetic response was determined by conventional metaphase analysis. Disease progression was defined by the incidence of accelerated phase, blastic phase or death from any reason. A landmark analysis was performed for progression free survival (PFS) and overall survival (OS). Results: Disease progression was observed in 149 patients (11.1%), 127 patients died (9.5%). After 3 months of treatment the median BCR-ABL IS was 2.6% (0-100), the median proportion of Philadelphia chromosome positive metaphases (Ph+) was 8% (0-100). The BCR-ABL landmarks of 1% and 10% after 3 months of imatinib both proved to discriminate significantly for PFS and OS: BCR-ABL IS 10% after 3 months resulted in a significant difference between the poor risk group (>10%, n=195) and the intermediate risk group (1-10%, n=291): p=0.038 for PFS and p=0.012 for OS. The difference between the intermediate risk group and the good risk group (35% (n=123), p=0.022 for PFS, p=0.043 for OS; Ph+ \u226465% (n=401) vs. Ph+ >65% (n=84), p=0.004 for PFS and p=0.011 for OS. A 3 group stratification did not reach statistical significance. Conclusions: The achievement of molecular and cytogenetic response landmarks after 3 months of imatinib treatment is predictive for long term progression free and overall survival. At 3 months a BCR-ABL IS of 10% or more is associated with a 5-year overall survival of 87% suggesting an early change of treatment, whereas a BCR-ABL IS of 1% or less indicates a favorable 5-year overall survival of 97%. Disclosures: Schnittger: Mu\u0308nchner Leuka\u0308mie Labor: Equity Ownership. Haferlach: Mu\u0308nchner Leuka\u0308mie Labor: Equity Ownership. German CML Study Group: Deutsche Krebshilfe: Research Funding; Novartis: Research Funding; BMBF: Research Funding; EU: Research Funding; Roche: Research Funding; Essex: Research Funding."
}